This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
I read with great interest the results of the randomized trial by Koch-Henriksen et al.1 which compared weekly IFNβ-1a 22 μg, SC (Rebif) with every other day IFNβ-1b 250 μg, SC in the treatment of relapsing-remitting multiple sclerosis (RRMS). There are, however, several additional points of clarification and discussion that the authors need to provide so that the readership can place this study into proper context.
First, this 2-year trial finished enrollment in October 1997 and yet the results of this trial were not received by Neurology until February 2005.1 The authors need to explain the reason for the inordinate delay in the publication of this material.
Second, the authors currently (and inappropriately) frame their discussion in the context of the EVIDENCE and INCOMIN trials,2,3 each of which compared high-dose and low-dose IFNβ products of proven efficacy. By contrast, in the present study, the authors have compared high-dose IFNβ-1b against a product that was demonstrated in the OWIMS trial4 to be ineffective (a 0% relapse-rate reduction) in the treatment of RRMS. Thus, their study seems to show that IFNβ-1b 250 μg, SC …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
